Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Beyond GeneGPT: A Multi-Agent Architecture with Open-Source LLMs for Enhanced Genomic Question Answering
arXiv:2511.15061v1 Announce Type: new Abstract: Genomic question answering often requires complex reasoning and integration across diverse biomedical sources. GeneGPT addressed this challenge by combining domain-specific APIs with OpenAI's code-davinci-002 large language model to enable natural language interaction with genomic databases. However, its reliance on a proprietary model limits scalability, increases operational costs, and raises concerns about data privacy and generalization. In
-
cs.AI, q-bio.NC updates on arXiv.org
-
Diagnosing Hallucination Risk in AI Surgical Decision-Support: A Sequential Framework for Sequential Validation
arXiv:2511.00588v1 Announce Type: cross Abstract: Large language models (LLMs) offer transformative potential for clinical decision support in spine surgery but pose significant risks through hallucinations, which are factually inconsistent or contextually misaligned outputs that may compromise patient safety. This study introduces a clinician-centered framework to quantify hallucination risks by evaluating diagnostic precision, recommendation quality, reasoning robustness, output coherence, an
Diagnosing Hallucination Risk in AI Surgical Decision-Support: A Sequential Framework for Sequential Validation
-
Nature Medicine
-
A full life cycle biological clock based on routine clinical data and its impact in health and diseases
Nature Medicine, Published online: 27 October 2025; doi:10.1038/s41591-025-04006-wThe biological clock model LifeClock predicts biological age across all life stages from routine clinical data, revealing distinct pediatric and adult disease risk patterns.
A full life cycle biological clock based on routine clinical data and its impact in health and diseases
Nature Medicine, Published online: 27 October 2025; doi:10.1038/s41591-025-04006-w
The biological clock model LifeClock predicts biological age across all life stages from routine clinical data, revealing distinct pediatric and adult disease risk patterns.-
Omics in Gastric
-
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strategies
Biomark Res. 2025 Aug 11;13(1):101. doi: 10.1186/s40364-025-00812-z.ABSTRACTBACKGROUND: Early identification of high-risk individuals is crucial for optimizing cancer screening, particularly when considering expensive and invasive methods such as multi-omics technologies and endoscopic procedures. However, developing a robust, practical multi-cancer risk prediction model that integrates diverse, multi-scale data and with proper validation remains a significant challenge.METHODS: We initialized t
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strategies
Biomark Res. 2025 Aug 11;13(1):101. doi: 10.1186/s40364-025-00812-z.
ABSTRACT
BACKGROUND: Early identification of high-risk individuals is crucial for optimizing cancer screening, particularly when considering expensive and invasive methods such as multi-omics technologies and endoscopic procedures. However, developing a robust, practical multi-cancer risk prediction model that integrates diverse, multi-scale data and with proper validation remains a significant challenge.
METHODS: We initialized the FuSion study by recruiting 42,666 participants from Taizhou, China, with a discovery cohort (n = 16,340) and an independent validation cohort (n = 26,308) after exclusion criteria. We integrated multi-scale data from 54 blood-derived biomarkers and 26 epidemiological exposures to develop a risk prediction model for five common cancers, including lung, esophageal, liver, gastric, and colorectal cancer. Employing five supervised machine learning approaches, we used a LASSO-based feature selection strategy to identify the most informative predictors. The model was trained and internally validated in the discovery cohort, externally applied in the validation cohort, and further evaluated through a prospective clinical follow-up to assess cancer events via clinical examinations.
RESULTS: The final model comprising four key biomarkers along with age, sex, and smoking intensity, achieving an AUROC of 0.767 (95% CI: 0.723-0.814) for five-year risk prediction. High-risk individuals (17.19% of the cohort) accounted for 50.42% of incident cancer cases, with a 15.19-fold increased risk compared to the low-risk group. During follow-up of 2,863 high-risk subjects, 9.64% were newly diagnosed with cancer or precancerous lesions. Notably, cancer detection in the high-risk group was 5.02 times higher than in the low-risk group and 1.74 times higher than in the intermediate-risk group. In particular, the incidence of esophageal cancers in the high-risk group was 16.84 times that of the low-risk group.
CONCLUSIONS: This is the first population-based prospective study in a large Chinese cohort that leverage multi-scale data including biomarkers for multi-cancer risk prediction. Our effective risk stratification model not only enhances early cancer detection but also lays the foundation for the targeted application of advanced screening methods, including but not limited to multi-omics technologies and endoscopy. These findings support precision prevention strategies and the optimal allocation of healthcare resources.
PMID:40790537 | PMC:PMC12341305 | DOI:10.1186/s40364-025-00812-z
-
Nature - Issue - nature.com science feeds
-
Synthetic lethality of mRNA quality control complexes in cancer
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08398-6PELO–HBS1L and SKI complexes in the human mRNA quality control pathway exhibit a synthetic lethal interaction and may represent novel targets for the development of cancer therapies.
Synthetic lethality of mRNA quality control complexes in cancer
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08398-6
PELO–HBS1L and SKI complexes in the human mRNA quality control pathway exhibit a synthetic lethal interaction and may represent novel targets for the development of cancer therapies.